Mariner 13F: Adds $5.6M to BioMarin Pharmaceutical (BMRN) Stake
Mariner boosted its position in BioMarin Pharmaceutical to 268,901 shares, reflecting a 54% increase.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mariner added 94,617 shares to its stake in BioMarin Pharmaceutical Inc. ($BMRN), a 54.29% increase, according to a 13F filing with the SEC dated May 13, 2026. It reported 268,901 shares worth $15.87 million at the end of the quarter.
Since the filing, $BMRN is down 6.3% after 1 week, up 4.5% after 1 month and up 2.1% to date (from the $53.55 close on May 13, 2026).
BMRN
BioMarin Pharmaceutical Inc.
Key Points
- Mariner increased its stake in BioMarin Pharmaceutical by 54%, adding 94,617 shares to reach a total of 268,901 shares valued at $15.87 million.
- BioMarin's stock traded near $59.00 on Saturday, with a market cap of $11.40 billion and a forward P/E ratio of 9.13.
- Analysts from Canaccord Genuity, B of A Securities, and Citigroup have issued 'buy' ratings, with price targets up to $119.00.
Get $BMRN trade alerts by text
We text you when insiders, Congress or big funds trade $BMRN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BioMarin Pharmaceutical Inc. alert may contain errors. Disclosures
Mariner has increased its stake in BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN) by 54.3%, according to its latest filing with the SEC. The fund added 94,617 shares, bringing its total to 268,901 shares, which are valued at approximately $15.87 million as of the reporting period.
Mariner vs. the S&P 500
Hypothetical returns from Mariner's disclosed trades, not real profit or advice. How we model this.
What Changed in Mariner's BioMarin Pharmaceutical Position
Mariner significantly boosted its holdings in BioMarin Pharmaceutical, adding 94,617 shares to its portfolio. This increase brought its total to 268,901 shares from the previous 174,284 shares, representing a 54.3% increase in its position.
Other Institutional Activity in BioMarin Pharmaceutical
Other major funds have also been active in BioMarin Pharmaceutical. BlackRock, Inc. grew its holdings by 683,193 shares, ending with 19,818,301 shares valued at about $1.12 billion. Dodge & Cox slightly reduced its stake by 10,625 shares, resulting in 14,561,759 shares worth approximately $822.59 million. Primecap Management Co/CA/ cut its position by 355,309 shares, leaving it with 14,194,005 shares valued at $801.82 million. Meanwhile, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions, each acquiring over 8 million shares valued at $488.25 million and $468.78 million, respectively.
BioMarin Pharmaceutical Inc. Stock Down 7.7%
Shares of BioMarin Pharmaceutical traded near $59.00 on Saturday. The company has a market capitalization of $11.40 billion, with a P/E ratio of 42.45 and a forward P/E of 9.13. Its beta is 0.24, suggesting lower volatility compared to the market. The stock's 52-week range is between $49.26 and $66.28, with a 50-day moving average of $54.45 and a 200-day moving average of $55.67. BioMarin maintains a strong financial position with a current ratio of 5.81 and a quick ratio of 3.94.
Recent Earnings
For the most recent quarter, BioMarin Pharmaceutical reported revenue of $3.24 billion, reflecting a growth rate of 2.8%. The company achieved an earnings per share (EPS) of $1.39, with a net margin of 8.3% and a return on equity (ROE) of 4.5%. The next earnings release is scheduled for August 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
6 target cuts vs 3 raises.
-
EPS & revenue
EPS missed estimates by 29.5%. Revenue missed estimates by 0.6%.
-
Profit surprise
EBITDA missed by 14 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
3 target raises, 6 target cuts.
-
Earnings quality
Gross margin down 5.1 points. Operating margin down 13.1 points. Positive free cash flow.
Earnings Call Summary
The company closed its acquisition of Amicus last week and is integrating two therapies for rare genetic disorders. Q1 revenue of 766 million dollars was below guidance due to order timing from strong Q4 orders, but patient demand remains robust with Voxzogo patient growth up 20 percent year over year and new adolescent label for Palynziq driving physician engagement. Management expects Q2 EPS to be only modestly higher than Q1 due to pre-close acquisition costs and revenue timing weighted to later quarters, but pivotal data readouts for Voxzogo in hypochondroplasia and BMN-401 are expected in Q2.
Guidance BioMarin raised full year revenue guidance to 3.825 to 3.925 billion dollars after closing the Amicus acquisition, which adds Galafold and Pombility to their Enzyme Therapies portfolio. They expect 20 percent revenue growth in 2026 at the midpoint, with about 55 percent of annual revenue coming in the second half of the year due to order timing and eight months of Amicus product sales beginning in May.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at BioMarin Pharmaceutical Inc.
Several insiders have been buying shares of BioMarin Pharmaceutical. On June 2, 2026, insiders including Mark Enyedy, Athena Countouriotis, Timothy Walbert, Barbara Bodem, Maykin Ho, and Robert Hombach each purchased 7,490 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On May 22, 2026, Canaccord Genuity maintained its 'buy' rating on BioMarin Pharmaceutical with a price target of $111.00. B of A Securities also maintained a 'buy' rating with a target of $80.00 on May 19, while Citigroup initiated coverage with a 'buy' rating and a $75.00 target on the same day. The consensus among 26 analysts is a 'buy' with an average target price of $87.85.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company based in San Rafael, California. It specializes in developing and commercializing therapies for rare and serious diseases. The company operates globally, providing treatments for conditions like mucopolysaccharidosis and phenylketonuria. BioMarin's products include VIMIZIM, VOXZOGO, and PALYNZIQ, among others, and it continues to develop new therapies to address unmet medical needs. Led by CEO Mr. Alexander Hardy, BioMarin employs over 3,200 people.
Bottom Line
Mariner's recent increase in its stake in BioMarin Pharmaceutical highlights its confidence in the company's potential. Investors often track such filings to gauge institutional sentiment. It's important to note that 13F filings are historical and may not reflect current positions.
Related Filing Alerts
Source: Mariner's 13F filing on $BMRN (May 13, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Mariner 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts